What are the dosing guidelines, contraindications, and monitoring recommendations for Jornay PM (extended‑release methylphenidate) in patients aged 6 years and older?

Jornay PM Dosing, Contraindications, and Monitoring

Jornay PM (extended-release methylphenidate) should be initiated at 20 mg taken once daily in the evening (between 6:30-9:30 PM, typically 8:00 PM) in patients 6 years and older, with weekly titration in 20 mg increments up to a maximum of 100 mg daily. 1

Dosing Guidelines

Starting Dose and Titration

• Initial dose: 20 mg once daily in the evening 1
• Timing window: 6:30 PM to 9:30 PM (most commonly 8:00 PM) 1
• Titration: Increase weekly by 20 mg increments 1
• Maximum dose: 100 mg daily (doses above 100 mg have not been studied) 1
• Timing optimization: Adjust administration time within the 6:30-9:30 PM window to optimize next-morning tolerability and all-day efficacy, then maintain consistent timing 1

Administration Instructions

• Take consistently either with or without food 1
• Capsules may be swallowed whole OR opened and sprinkled entirely onto applesauce (consume immediately without chewing; do not divide dose) 1
• Critical: Do NOT take in the morning 1
• Missed dose: If remembered same evening, take as soon as possible; if remembered next morning, skip and wait for next scheduled evening dose 1

Switching from Other Methylphenidate Products

Do NOT substitute on a milligram-per-milligram basis - Jornay PM has different pharmacokinetic properties and methylphenidate base composition compared to other formulations 1. Discontinue the previous methylphenidate product and titrate Jornay PM from 20 mg using the standard schedule above.

Contraindications

Jornay PM is absolutely contraindicated in: 1

1. Hypersensitivity: History of hypersensitivity to methylphenidate or any component (angioedema and anaphylaxis have been reported)
2. MAOI use: Concurrent treatment with MAOIs or use within the preceding 14 days 1

Pretreatment Screening Requirements

Before prescribing, assess for: 1

1. Cardiac disease: Perform careful personal and family history of sudden death or ventricular arrhythmia, plus physical examination
2. Tics/Tourette's: Evaluate family history and clinically assess for motor or verbal tics or Tourette's syndrome
3. Abuse risk: Assess each patient's risk for abuse, misuse, and addiction given the high potential for substance use disorder development 1

Monitoring Recommendations

Cardiovascular Monitoring

• Blood pressure and pulse: Monitor regularly throughout treatment 1
• Research shows methylphenidate causes small but consistent increases in pulse rate, systolic and diastolic blood pressure over 24 months 2
• Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, or other serious cardiac disease 1

Growth Monitoring

• Height and weight: Closely monitor in pediatric patients 1
• Interrupt treatment in children not growing or gaining weight as expected 1
• Long-term data (2 years) shows minimal impact on growth velocity, with no significant height reduction compared to non-medicated ADHD controls 2

Psychiatric Monitoring

• Screen for manic episode risk factors before initiating 1
• Monitor for emergence of psychotic or manic symptoms; consider discontinuation if these occur 1
• Throughout treatment, frequently monitor for signs of abuse, misuse, and addiction 1

Neurological Monitoring

• Regularly monitor for emergence or worsening of tics or Tourette's syndrome; discontinue if clinically appropriate 1

Ophthalmologic Considerations

• Patients at risk for acute angle closure glaucoma (e.g., significant hyperopia) should be evaluated by an ophthalmologist 1
• Prescribe cautiously to patients with open-angle glaucoma or increased intraocular pressure; closely monitor these patients 1

Other Monitoring

• Peripheral vasculopathy/Raynaud's phenomenon: Careful observation for digital changes; consider rheumatology referral if signs develop 1
• Priapism: Educate patients to seek immediate medical attention for abnormally sustained or frequent painful erections 1

Special Population: Age Restrictions

Jornay PM is NOT recommended in children younger than 6 years - this population had higher plasma exposure and higher incidence of adverse reactions (particularly weight loss) at the same dosages compared to older children 1. This aligns with general ADHD guidelines recommending methylphenidate as first-line for preschool-aged children only with moderate-to-severe ADHD after behavioral interventions fail, though such use remains off-label 3.

Dosage Adjustment and Discontinuation

• If paradoxical aggravation or adverse reactions occur: Reduce dose or discontinue 1
• If no improvement after one month of appropriate dosage adjustment: Discontinue 1
• Educate patients and families about proper storage and disposal of unused medication given abuse potential 1